Case Study:
Patient Identification for Faster Treatment
Patient Identification for Faster Treatment
Sometimes conditions that are not rare diseases still offer the same types of challenges in some situations. Sometimes finding the patients can be like finding a needle in a haystack. This product was in oncology but offered the same challenges as a rare disease drug in terms of finding the patients.
The Client Problem
• Had a 3rd Line Cancer product and many patients died at 2L so the 3L patients were rare and difficult to find
• Turned to Eularis to see if AI could identify and recruit more patients
The Solution
• Use big data (EHR and claims) and AI to:
◦ Identify and examine all previous 3L patients to predict what it was that increased probability of a patient reaching 3L+
◦ Identify the 2L patients who had the greatest probability of progressing
◦ Identify who their physicians were
◦ Created a visualization of all potential patient locations and could pull up doctor ID and other data on physician to allow the sales reps to prioritize who they saw
The Outcome
• Identified all possible 3L patients found in the EHR
• Were able to notify rep about the patient and physician even before they knew the patient would be 3L
• Were able to ensure that the physician was ready for the patients when they did progress and was aware of the benefits of the client drug for those situations where it was clinical appropriate
To achieve these kinds of results, contact Eularis today.
Latest News
Read our latest blogs here.
Why Embedding Artificial Intelligence is Critical for Successful Digital Marketing
Everyone does digital marketing, and everybody is doing more of it these days. Consider these statistics: According to Cropink reports that over 376 billion emails
Leadership Redefined: Thriving Alongside Intelligent Machines
Your next job, loan rejection or course homework assignment may be assessed by an algorithm that works round the clock, never rests, never explains and never
Navigating Pharma Budget Cuts: Innovation Is The Key
Shockingly, many layoff trackers exist in the pharma world. Each paints the same picture: patent cliffs and turbulent market conditions have led to pharma budget